| 11.21 0.11 (0.99%) | 02-07 18:39 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 16.1 | 1-year : | 18.81 |
| Resists | First : | 13.78 | Second : | 16.1 |
| Pivot price | 9.17  |
|||
| Supports | First : | 8.08 | Second : | 4.55 |
| MAs | MA(5) : | 10.61 |
MA(20) : | 8.9 |
| MA(100) : | 7.41 |
MA(250) : | 8.51 |
|
| MACD | MACD : | 0.8 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 70.3 |
D(3) : | 70.7 |
| RSI | RSI(14): 59.7 |
|||
| 52-week | High : | 19 | Low : | 4.55 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ INKT ] has closed below upper band by 21.3%. Bollinger Bands are 207.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 35 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 12.01 - 12.05 | 12.05 - 12.1 |
| Low: | 10.72 - 10.77 | 10.77 - 10.82 |
| Close: | 11.13 - 11.21 | 11.21 - 11.28 |
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Sun, 02 Feb 2025
MiNK Therapeutics, Inc. (NASDAQ:INKT) Sees Significant Growth in Short Interest - MarketBeat
Thu, 23 Jan 2025
MiNK Therapeutics Targets Immune Reconstitution to Combat - GlobeNewswire
Thu, 23 Jan 2025
MiNK Therapeutics presents cancer study at ASCO GI By Investing.com - Investing.com South Africa
Tue, 21 Jan 2025
MiNK Therapeutics announces reverse stock split - Investing.com
Wed, 18 Dec 2024
MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting - GlobeNewswire
Thu, 14 Nov 2024
MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 74.6 (%) |
| Held by Institutions | 2.2 (%) |
| Shares Short | 52 (K) |
| Shares Short P.Month | 49 (K) |
| EPS | -3.71 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.52 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -97.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.36 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -3.03 |
| PEG Ratio | 0 |
| Price to Book value | -21.56 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.68 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|